



1072417

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

BORMAN et al.

Atty. Ref.: 620-410

Serial No. 10/564,010 ✓

Group: unknown

Filed: January 10, 2006

Examiner: Unknown

For: 5-HT2B RECEPTOR ANTAGONISTS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

May 10, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **N/C**

2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)


a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

## CITATION

620-410

10/564,010

## APPLICANT


BORMAN et al.

## FILING DATE

January 10, 2006

## GROUP

unknown



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	EXAMINER & TRADEMARK OFFICE NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

TRANSLATION

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	DE 198 51 421	05/2000	Germany				
	EP 0 710 654	05/1996	Europe				
	FR 1 513 739	02/1968	France				
	GB 681 712	10/1952	Great Britain				
	GB 2 230 527	10/1990	Great Britain				
	RO 63449	05/1978	Romania				
	WO 96/20932	07/1996	WIPO				
	WO 94/09017	04/1994	WIPO				
	WO 2004/009017	01/2004	WIPO				
	WO 03/068226	08/2003	WIPO				
	WO 96/24351	08/1996	WIPO				
	WO 01/08668	02/2001	WIPO				
	WO 03/006443	01/2003	WIPO				
	WO 03/072569	09/2003	WIPO				
	WO 02/083628	10/2002	WIPO				
	WO 01/28561	04/2001	WIPO				
	WO 01/19801	03/2001	WIPO				
	WO 98/16515	04/1998	WIPO				
	WO 95/03286	02/1995	WIPO				
	WO 01/14372	03/2001	WIPO				
	WO 00/23444	04/2000	WIPO				
	WO 95/24200	09/1995	WIPO				
	WO 02/092576	11/2002	WIPO				
	WO 97/44326	11/1997	WIPO				

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)


	Hoyer et al, Pharmacological Review, 1994, Vol. 46, No. 2, pp 157-203
	Kato et al, Chem. Pharm. Bull. 1977, Vol. 25, No. 2, pp 215-220
	Launay et al, Nature Medicine, 2002, Vol. 8, No. 10, pp 1129-1135
	van Leusen et al, J. Org. Chem. 1981, Vol. 46, pp 2069-2072
	Marchetti, J. Med. Chem. 1968, Vol. 11, pp 1092-1093

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-410	10/564,010
 (Use several sheets if necessary)		APPLICANT	
		BORMAN et al.	
FILING DATE January 10, 2006		GROUP	
		unknown	
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)</b>			
Martin et al, Neuropharmacology, 1994, Vol. 33, No. 3/4 pp 261-273 Molina et al, Synthesis, 1993, Vol. 1, pp 54-56 Nath et al, Indian J. Chem., 1980, Vol. 19B, pp 526-529 Newton et al, Global Outsourcing Review, 2003, Vol. 5, No. 2, pp 1-5 Nishiwaki, Chem. Pharm. Bull., 1962, Vol. 10, pp 1029-1032 O'Brien et al, J. Org. Chem., 1962, Vol. 27, pp 1104-1107 Pattanayak et al, Indian J. Chem., 1978, Vol. 16B, pp 1030-1032 Pattanayak et al, J. Indian Chem. Soc., 1978, Vol. LV, pp 264-267 Phillips et al, J. Am. Chem. Soc., 1952, Vol. 74, pp 3922-3924 Rahman et al, Bioorganic & Medicinal Chemistry Letters, 2003, Vol. 13, pp 1119-1123 Reiter et al, J. Heterocyclic Chem., 1986, Vol. 23, pp 401-408 Tanaka et al, Chem. Abs. 1967, 66:94930 Tidwell et al, Journal of Medicinal Chemistry, 1978, Vol. 21, No. 7, pp 613-623 Vullo et al, Bioorganic & Medicinal Chemistry Letters, 2003, Vol. 13, pp 1005-1009 Watanabe et al, Chem. Pharm. Bull., 1987, Vol. 35, No. 4, pp 1452-1459 Ainley et al, J. Chem. Soc., 1953, pp 59-70 Ali et al, Bioorganic & Medicinal Chemistry Letters, 2001, Vol. 11, pp 2185-2188 Banks, J. Am. Chem. Soc., 1944, Vol. 66, No. 7, 1131 Bansal, Chem. Abs. 2000:100697 Bansal et al, Oriental Journal of Chemistry, 1999, Vol. 15, No. 3, pp 489-494 Bansal et al, Indian Journal of Chemistry, 2000, Vol. 39B, pp 357-362 Bansal et al, Eur. J. Med. Chem., 2001, Vol. 36, pp 81-92 Berge et al, Journal of Pharmaceutical Sciences, 1977, Vol. 66, No. 1, pp 1-19 Berger et al, JID, 1996, Vol. 174, pp 659-662 Blank et al, Journal of Medicinal Chemistry, 1972, Vol. 15, No. 6, pp 694-696 Cavalleri et al, IL Farmaco - Ed. Sc., 1976, Vol. 31, pp 393-402 Cavalleri et al, Arzneim.-Forsch./Drug Res., 1977, 27 (II), No. 10, pp 1889-1895 Cockerill et al, Synthesis, 1976, pp 591-593 Cooper et al, J. Med. Chem., 1990, Vol. 33, pp 1246-1252 Crank et al, Journal of Medicinal Chemistry, 1971, Vol. 14, No. 11, pp 1075-1077			

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**Examiner** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**Form PTO-FB-A820 (Also PTO-1449)**